Practical considerations in future psoriasis therapies - 24/08/11
Doi : 10.1016/S0733-8635(03)00128-1
Christy Riddle, MD a, Melodie Young, MSN, RN ⁎, b, c 
, Alan Menter, MD a, c
, Alan Menter, MD a, c a Department of Internal Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
b Graduate School of Nursing, The University of Texas at Arlington, Arlington, TX, USA
c Texas Dermatology Associates, 5310 Harvest Hill Road, Suite 260, Dallas, TX 75230, USA
*Corresponding author. Texas Dermatology Associates, 5310 Harvest Hill Road, Suite 260, Dallas, TX 75230
Plan
 | Alan Menter has the following conflicts of interest: (1) research: Abbott, Allergan, Allermed, Amgen, Astralis, Biogen, Centocor, Connetics, Corixa, Dermik, Dow, Ferndale, Fujisawa, Galderma, Genzyme, GlaxoSmithKline, Inamed, Lumenis, Medicis, Novartis, Otsuka, Photocure, Regeneratio, Pharma AG, Scirex, Serono, Thermosurgery; and (2) consultancies and honoraria: Allergan, Amgen, Biogen, Centocor, Genentech, ICN, Novartis, Serono, Thermosurgery, Warner-Chilcott. No stock ownership. Melodie Young has the following conflicts of interest: Nurse Advisory Boards for Biogen, Fujisawa, and Genentech. Presentations for Allergan, Amgen, Biogen, Fujisawa, Genentech, Healthpoint, and ICN. |
© 2004
Elsevier Inc. Tous droits réservés.
Vol 22 - N° 4
P. 487-492 - octobre 2004 Retour au numéro
Article précédent
- Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist
- Eric M. Ruderman, Siddharth Tambar
- Psoriasis: future research needs and goals for the twenty-first century
- Christopher E.M. Griffiths
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?